Amgen, Inc. chief technology officer David Reese, who recently handed over his prior title of EVP of research and development to Jay Bradner, explained in an interview with Scrip during this month’s J.P. Morgan Healthcare Conference that the transition to his new role at the company was a decade in the making. He and former Novartis AG executive Bradner will be working closely together to integrate artificial intelligence and other technologies into Amgen’s R&D operations.
Amgen Doubles Down On AI, Genomic Investments In R&D
New Tech, R&D Heads ‘Joined At The Hip’
David Reese, chief technology officer and former EVP of R&D, and newly appointed EVP of R&D Jay Bradner spoke with Scrip about how Amgen is pairing artificial intelligence with genomics plus data milestones in 2024.
